Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from Starpharma Holdings Limited ( (AU:SPL) ).
Starpharma showcased its DEP® dendrimer platform at the 24th Annual PepTalk conference, focusing on targeted radioligand therapies and precision medicine for cancer. Highlighting the platform’s potential to improve radiotheranostic payload delivery to tumors, the presentation emphasized benefits such as enhanced diagnostic profiles and increased specificity, offering opportunities for collaboration with key companies in the radiotheranostic field.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company with two decades of experience in dendrimer technology, focusing on improving health outcomes and quality of life for patients with significant illnesses, such as cancer. The company’s portfolio includes clinical-stage DEP® assets, preclinical radiopharmaceutical assets, research collaborations, and commercially marketed over-the-counter products.
YTD Price Performance: 7.14%
Average Trading Volume: 6,312
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $31.03M
Learn more about SPL stock on TipRanks’ Stock Analysis page.
